Actilyse

Main information

  • Trade name:
  • Actilyse 50 mg Injection with diluent
  • Dosage:
  • 50 mg
  • Pharmaceutical form:
  • Injection with diluent
  • Units in package:
  • Ampoule, 50 mL
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • Boehringer Ingelheim Pharma GmbH & Co KG

Documents

Localization

  • Available in:
  • Actilyse 50 mg Injection with diluent
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • ACTILYSE is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 4767
  • Authorization date:
  • 19-03-1987
  • Last update:
  • 27-09-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

ACTILYSE NZ CMI v01

Actilyse

®

Injection with diluent

alteplase, rch

Consumer Medicine Information

What is in this leaflet

This leaflet answers some common

questions about Actilyse.

It does not contain all the available

information. It does not take the place

of talking to your doctor or

pharmacist.

All medicines have risks and benefits.

Your doctor has weighed the risks of

you being treated with Actilyse

against the benefits they expect it will

have for you.

If you have any concerns about

being treated with this medicine,

ask your doctor or pharmacist.

This leaflet was last updated on the

date at the end of this leaflet. More

recent information may be available.

The latest Consumer Medicine

Information is available from your

pharmacist, doctor, or from

www.medsafe.govt.nz/

Consumers/cmi/CMIForm.asp and

may contain important information

about the medicine and its use of

which you should be aware.

Keep this leaflet.

You may need to read it again.

What Actilyse is used

for

Actilyse is used to treat a number of

conditions caused by blood clots

forming within blood vessels,

including:

heart attacks caused by blood clots

in the arteries of the heart

(myocardial infarction)

blood clots in the arteries of the

lung (pulmonary embolism)

stroke caused by a blood clot in an

artery of the brain (acute ischaemic

stroke).

Actilyse contains the active ingredient

alteplase. It belongs to a group of

medicines called thrombolytic agents.

Actilyse works by dissolving clots in

the blood vessels. These clots cause

disease by interfering with normal

blood flow.

Ask your doctor if you have any

questions about why this medicine

has been prescribed for you.

Your doctor may have prescribed it

for another reason.

Before you are given

Actilyse

When you must not be given

it

You should not be given Actilyse if

you have an allergy to:

any medicine containing alteplase

(the active ingredient in Actilyse)

gentamycin (an antibiotic)

natural rubber (also called latex

which is part of the packaging

material)

any of the ingredients listed at the

end of this leaflet.

Some of the symptoms of an allergic

reaction may include:

shortness of breath

wheezing or difficulty breathing

swelling of the face, lips, tongue or

other parts of the body

rash, itching or hives on the skin.

Because of the risk of bleeding,

Actilyse should not be given to you if

you have, or have had:

current bleeding or severe bleeding

in the past 6 months

a family history of bleeding

disorders or a tendency to bleed

a previous condition resulting in

bleeding or suspected bleeding in

the brain

heart and lung resuscitation,

childbirth, organ biopsy or an

invasive medical procedure in the

past 10 days

major surgery, including heart,

head or spinal surgery, or

significant trauma (including

trauma to the head) in the past 10

days

severe and uncontrolled high blood

pressure

tumours in which the risk of

bleeding is increased

any blood clotting defect

ACTILYSE NZ CMI v01

current treatment with other

thrombolytic agents (medicines

used for dissolving blood clots) or

an anti-clotting agent

(anticoagulant), such as warfarin

certain diseases of the blood

vessels, heart, brain, oesophagus,

stomach/

intestine, liver, kidney or pancreas

in which the risk of bleeding is

increased.

In addition to the above medical

conditions, Actilyse should not be

used for the treatment of heart attack

or pulmonary embolism if you have,

or have had:

a stroke caused by bleeding in the

brain (condition known as

haemorrhagic stroke) or a stroke of

unknown origin at any time

a stroke caused by a blood clot in

the artery of the brain (condition

known as ischaemic stroke) or a

transient ischaemic attack (TIA) in

the past 6 months, unless the

symptoms of your stroke occurred

within the past 4.5 hours and you

are about to be treated for it.

Actilyse should not be used for the

treatment of acute ischaemic stroke if

you have, or have had:

experienced the symptoms of your

stroke for more than 4.5 hours or if

you do not know when they began

only very mild symptoms or the

symptoms are rapidly improving

before receiving Actilyse

a very severe stroke

fits or seizures at the onset of

stroke

treatment with heparin in the past

48 hours (and abnormal bleeding

time)

previous stroke or serious head

injury/trauma within the last 3

months

previous stroke and you are

diabetic

a low platelet count (platelets are

blood cells involved in blood

clotting)

severe high blood pressure (over

185/110 mmHg)

abnormal blood glucose levels.

Do not give this medicine to a child

or adolescent under the age of 18

years.

Safety and effectiveness in children

and adolescents younger than 18 years

have not been established.

Actilyse should not be used after the

expiry date printed on the pack or if

the packaging is torn or shows signs of

tampering.

If you are not sure whether you

should be given this medicine, talk

to your doctor.

Before you are given it

It is important that your doctor knows

your medical history before

administering Actilyse.

Tell your doctor if you have allergies

to any other medicines, foods,

preservatives or dyes.

Tell your doctor if you have, or have

had, any of the following conditions:

a previous heart attack or any other

heart condition

a previous stroke caused by a

blood clot or a transient ischaemic

attack (TIA) more than 6 months

previously (this only applies for

treatment of heart attack or

pulmonary embolism)

diabetes mellitus

bleeding from inside or around

your eyes or visual disturbances

high blood pressure

severe liver disease

any recent medical procedure such

as a biopsy or injection.

If you are uncertain as to whether

you have, or have had, any of these

conditions you should raise those

concerns with your doctor.

Tell your doctor if you are pregnant

or plan to become pregnant or are

breastfeeding.

Your doctor can discuss with you the

risks and benefits involved.

Tell your doctor if you are over the

age of 80 years.

The risks of treatment with Actilyse

may be increased in any patient over

80 years of age.

Before starting treatment with

Actilyse your doctor will assess other

factors which may increase the risks

of using Actilyse. Your doctor will

take special care with Actilyse if you

have or have had:

any infected veins and cannula

sites

any condition in which bleeding is

a significant risk or would be

particularly difficult to manage

because of its location

ever received Actilyse before.

If you have not told your doctor

about any of the above, tell him/her

before you are given Actilyse.

Taking other medicines

Tell your doctor if you are taking

any other medicines, including any

that you get without a prescription

from your pharmacy, supermarket

or health food shop.

Some medicines and Actilyse may

interfere with each other. These

include:

aspirin, heparin, warfarin or any

other medicines used to “thin” the

blood and prevent blood clots

ACE inhibitors, a group of

medicines used to treat high blood

pressure.

These medicines may be affected by

Actilyse or may affect how well it

works. You may need different

ACTILYSE NZ CMI v01

amounts of your medicines, or you

may need to take different medicines.

Your doctor and pharmacist have

more information on medicines to be

careful with or avoid while using this

medicine.

How Actilyse is given

Actilyse will be prepared and

administered to you by your doctor or

by a healthcare professional. It is not

for self-administration.

Treatment with Actilyse should be

initiated as soon as possible after the

start of your symptoms.

Actilyse is supplied as a powder and

sterilised water for injections. Before

use, the water for injections is added

to the powder to form a solution ready

for administration. This solution is

given into a vein through a drip line.

How much is given

The recommended dose is 100 mg

given over 90 or 180 minutes for a

heart attack, or over 120 minutes for

acute massive pulmonary embolism. A

lower dose (1.5 mg/kg) is

recommended for patients weighing

less than 65 kg. No more than 100 mg

should be given because it is

associated with a higher risk of

bleeding (especially in the brain).

For treatment of acute ischaemic

stroke a dose equivalent to 0.9 mg/kg

body weight is given over 60 minutes.

The maximum dosage should not

exceed 90 mg.

Your doctor might prescribe a

different dose or duration of treatment

to that described here.

If you want more information, ask

your doctor.

If you are given too much

(overdose)

Overdose is unlikely because Actilyse

is administered under medical

supervision.

Symptoms of an overdose may include

bleeding.

In the case of serious bleeding, your

doctor will immediately stop treatment

with Actilyse and heparin. Your

doctor will start appropriate treatment

to control the bleeding and, if

necessary, replace the lost blood.

While you are using

Actilyse

Things you must not do

You should not take aspirin for the

first 24 hours after treatment with

Actilyse.

Your doctor may give you an injection

with heparin if this is necessary.

Things to be careful of

Actilyse increases the risk of bleeding

and bruising. After treatment with

Actilyse medical staff will avoid

giving you injections or moving you

unless absolutely necessary.

Your doctor will probably continue to

treat you with heparin and aspirin after

treatment with Actilyse. This is to

reduce the risk of more blood clots

forming.

If you feel light-headed, dizzy or

faint when getting out of bed or

standing up, get up slowly.

Standing up slowly, especially when

you get up from bed or chairs, will

help your body get used to the change

in position and blood pressure.

If this problem continues or gets

worse, talk to your doctor.

Side effects

Tell your doctor as soon as possible

if you do not feel well while you are

being given Actilyse.

This medicine may have unwanted

side effects in a few people. All

medicines can have side effects.

Sometimes they are serious, most of

the time they are not. You may need

medical attention if you get some of

the side effects.

If you are over 80 years of age you

may have an increased chance of

getting side effects.

Do not be alarmed by the following

list of side effects. You may not

experience any of them.

Ask your doctor to answer any

questions you may have.

If any of the following happen, tell

your doctor immediately:

bleeding or blood clot within the

head or brain. Symptoms may

include collapse, sleepiness,

difficulty in speaking or slurred

speech, numbness or weakness of

the arms or legs, headache,

dizziness, visual disturbance,

confusion, loss of memory,

agitation, depression, weakness on

one side of the body, convulsions,

fits or seizures, psychosis, a severe

mental condition in which the

person loses contact with reality

and is unable to think and judge

clearly, difficulty swallowing

bleeding from the skin, mouth,

gums, nose, or eyes

bruising

bleeding or bruising where the

injection is given

nausea, vomiting or vomiting

blood or material that looks like

coffee grounds

bleeding from the back passage,

black sticky bowel motions

(stools) or bloody diarrhoea

ACTILYSE NZ CMI v01

blood in the urine

coughing up blood

changes in heart rate (fast, slow or

irregular), extra heart beats, weak

pulse

chest pain, pain behind the breast

bone, sometimes spreading to the

neck and shoulders

shortness of breath, tiring easily

after light physical activity such as

walking, waking up short of breath

at night

rapid, shallow breathing

cold, clammy or white skin

light-headedness

weakness

fluid retention in different parts of

the body, often first noticed as

swollen ankles and feet

restlessness

any symptoms of an allergic

reaction (e.g. rash, itching, hives

on the skin, swelling of the face,

lips, mouth, tongue, throat or other

parts of the body, shortness of

breath, wheezing or difficulty

swallowing or breathing)

high body temperature.

Due to the life-threatening nature of

the diseases for which Actilyse is

used, some deaths have occurred after

treatment. However, use of Actilyse in

large numbers of patients has shown

that when used as recommended, the

benefits outweigh the risks.

There have also been reports of

blockages of blood vessels following

treatment with Actilyse. This can lead

to organ failure (e.g. kidney failure).

Nausea and vomiting can occur after a

heart attack and may or may not be

increased by Actilyse.

The above list includes very serious

side effects. You may need urgent

medical attention.

Tell your doctor if you notice

anything that is making you feel

unwell.

Other side effects not listed above

may also occur in some people.

After being given

Actilyse

Storage

Actilyse will be stored in the

pharmacy or on the ward below 25ºC

and protected from light.

After mixing with sterile water for

injections, Actilyse should be used

immediately. If not used immediately,

the product may be stored in a

refrigerator (2-8ºC) for up to 24 hours.

Disposal

The reconstituted solution is for single

use only. Any unused solution or

waste material should be disposed in

accordance with the local

requirements.

Product Description

What it looks like

Actilyse is the brand name of your

medicine. It comes as a sterile white to

off-white powder in clear glass vials

containing 10 mg or 50 mg alteplase.

Actilyse powder must be mixed with

sterile water for injections before use.

When mixed, the resulting solution is

colourless to pale yellow.

Actilyse is available as a pack

containing one vial of powder and one

vial of sterile water for injections.

Ingredients

Active ingredient:

Each vial of Actilyse powder contains

10 mg or 50 mg of alteplase.

Inactive ingredients:

Actilyse powder also contains:

arginine

nitrogen

phosphoric acid

polysorbate 80.

Sodium hydroxide or phosphoric acid

may be added to adjust the acidity of

Actilyse.

A 10 mL or 50 mL vial of sterile

Water for Injections is provided for

mixing with the powder.

Supplier

Actilyse is supplied in New Zealand

Boehringer Ingelheim (N.Z.) Limited,

Auckland

This leaflet was prepared in April

2017.

® Actilyse is a registered trademark of

Boehringer Ingelheim

© Boehringer Ingelheim 2017

3-1-2019

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Loblaw Companies Limited recalls Life at Home 50 Count Indoor LED Microdot Icicle Lights

Due to a potential manufacturing defect the lights may overheat, posing a burn and fire hazard.

Health Canada

21-12-2018

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, Llc Issues Allergy Alert on Undeclared Almond and Cashew Tree-Nut in 10 Oz. Nutty Choco Pop Found in Chocolate Popcorn Gift Box, Holiday Crowd Pleaser and Crowd Pleaser Gifts

Funky Chunky, LLC of Eden Prairie, MN is recalling 10 oz Nutty Choco Pop Gift Box, 50 oz. Holiday Crowd Pleaser and 50 oz. Crowd Pleaser, because it may contain undeclared Almond and Cashew Tree Nut. People who have an allergy or severe sensitivity to Almonds and Cashews run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

29-11-2018

ANSES Newsletter in English - N°50 - November 2018

ANSES Newsletter in English - N°50 - November 2018

France - Agence Nationale du Médicament Vétérinaire

22-11-2018

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Safety and efficacy of Monteban® G100 (narasin) for ducks for fattening

Published on: Wed, 21 Nov 2018 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Monteban® G100 for ducks. Monteban® G100, containing narasin, is intended for the prevention of coccidiosis in ducks for fattening at a dose range of 60–70 mg/kg of complete feed. Narasin from Monteban® G100 is safe for ducks for fattening at a level of 70 mg/kg complete feed...

Europe - EFSA - European Food Safety Authority Publications

21-11-2018

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Safety and efficacy of Monteban® G100 (narasin) for chickens for fattening

Published on: Tue, 20 Nov 2018 The feed additive Monteban® G100, containing the active substance narasin, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening at a dose of 60–70 mg/kg complete feed. Narasin is produced by fermentation. Limited data on the taxonomic identification of the production strain did not allow the proper identification of strain NRRL 8092 as Streptomyces aureofaciens. The FEEDAP Panel cannot conclude on the absence of genetic determinants for ...

Europe - EFSA - European Food Safety Authority Publications

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

25-7-2018

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

AMPI Recalls Limited Amount of Dry Whey Powder Because of Possible Health Risk

Associated Milk Producers Inc. (AMPI) of New Ulm, Minn., is recalling dry whey powder packaged in 50-pound and 25-kg bags that were produced at the cooperative’s Blair, Wis., dry whey plant from May 1-5, 2018; May 24-29, 2018; June 2-5, 2018; and June 7-14, 2018 due to the potential to be contaminated with Salmonella. This is a precautionary recall. All products shipped to the marketplace tested negative for Salmonella.

FDA - U.S. Food and Drug Administration

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration

19-9-2018

Targretin (Eisai GmbH)

Targretin (Eisai GmbH)

Targretin (Active substance: bexarotene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6098 of Wed, 19 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/326/T/50

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety